O'Donnell: better to come from Smith & Nephew in H2
This article was originally published in Clinica
Executive Summary
Smith & Nephew CEO Chris O'Donnell last week said that impressive first-half 2002 sales gain of 18% (including 4% from acquisitions) would be bettered in the second half on the strength of sound growth in its three core businesses. Endoscopy (sales rise 14%), orthopaedics (20%) and wound management (18%) all contributed to first- half sales of $551m ($827m). Analysts said the overall growth was 2% higher than consensus targets.